483
ProMed Pharma, LLCFDA 483 - ProMed Pharma, LLC - October 17, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of ProMed Pharma, LLC in Plymouth, MN, a drug manufacturer, revealed a significant quality system deficiency. The firm failed to adhere to its own written procedures for conducting annual product reviews, which were established in a technical and quality agreement and detailed in an internal Standard Operating Procedure. This indicates a lapse in ensuring consistent product quality and compliance with regulatory expectations.
Open in Dashboard
ID · 4f966410-a24b-4abd-85b0-b94f14f123d3